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Background: Diseases that affect the buccal cavity are a public health concern nowadays. 
Chlorhexidine and nystatin are the most commonly used drugs for the control of buccal 
  affections. In the search for more effective antimicrobials, nanotechnology can be successfully 
used to improve the physical chemical properties of drugs whilst avoiding the undesirable side 
effects associated with its use. Herein described are studies using nystatin and chlorhexidine 
with sodium montmorillonite (MMTNa), and chlorhexidine with β-cyclodextrin and two 
derivatives methyl-β-cyclodextrin and hydroxypropyl-β-cyclodextrin in the development of 
antimicrobial nanosystems.
Methods: The nanosystems were prepared by kneading and solubilization followed by freeze-
drying technique. The nanosystems were characterized by X-ray powder diffraction (XRPD), 
differential scanning calorimetry (DSC), and Fourier transform infrared spectroscopy (FTIR). 
Nanosystem antimicrobial activity against Streptococcus mutans and Candida albicans strains 
was evaluated with inhibition halo analysis.
Results: The nanocarriers MMTNa and cyclodextrins showed good yields. XRPD, FTIR, 
and DSC analysis confirmed the proposed nanosystems formation and the suitability of the 
production methods. The nanosystems that showed best antimicrobial effect were chlorhexi-
dine gluconate (CHX) and cyclodextrin inclusion complexes and CHX:MMTNa 60% cation 
exchange capacity – 24 hours.
Conclusion: The nanosystem formulations present higher stability for all chlorhexidine 
  inclusion complexes compared with pure chlorhexidine. The nystatin nanosystems have the 
potential to mask the bitter taste, justifying subsequent in-vivo studies. For these reasons, 
further studies are being carried out to evaluate their application in professional formulations.
Keywords: sodium montmorillonite, chlorhexidine gluconate, buccal diseases,   nanotechnology, 
cyclodextrins
Introduction
Diseases that affect the buccal cavity are considered a serious public health problem. 
Among the more prevalent are caries, periodontal disease, and the different types 
of oral candidiasis. Periodontal diseases and dental caries are usually caused by the 
presence of biofilm as a result of ineffective mechanical oral hygiene practices. For 
this reason, chemical agents are important to reduce gingivitis, periodontal disease, 
and dental caries.1 Candida albicans has already been isolated from the dental bio-
film, caries, and the periodontal pockets, which together with Streptococcus mutans 
has more severe consequences.2 There are also several clinical issues associated International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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with C. albicans which represent serious problems for 
treatment and prophylaxis.3 Therefore, the development of 
more effective therapies to treat these diseases is one of the 
major public dental health challenges. Chlorhexidine glu-
conate (CHX) is an antiseptic agent widely used to inhibit 
the formation of gingivitis and periodontitis.4 This cationic 
biguanidine interacts with the bacterial anionic surface and 
alters the integrity of the bacterial cell membrane leading 
to cytoplasm precipitation.5   However, besides the usual 
stability problems, this drug presents frequent side effects 
including taste perception alteration and an increase in tooth 
discoloration.6,7 For these reasons, several cyclodextrin 
(CD) inclusion complexes have been developed to increase 
stability and improve antimicrobial activity.4,8 The synergic 
association of CHX and nystatin (NYS) is a good option for 
the simultaneous control of C. albicans and S. mutans. Like 
CHX, NYS has an unpleasant flavor that leads to nausea 
during oral application, limiting its use and reducing patient 
compliance despite its undoubted effectiveness in the control 
of candidiasis and other buccal cavity disorders.9 The for-
mulation of nanostructured NYS and CHX could overcome 
the low solubility and stability problems of these drugs, 
producing a controlled release system with new improved 
antimicrobial activity. Previous reports have shown that a 
NYS and CHX β-cyclodextrin (βCD) inclusion can improve 
stability and solubility.4,10 However, better results can be 
obtained using nanocarriers with sustained release proper-
ties, such as sodium montmorillonite (MMTNa), the main 
constituent of bentonite (60%). This nanocarrier may present 
some synergistic effect due to the capability of these materi-
als to adsorb and fix bacteria and fungi, immobilizing their 
toxins,11 and also presents parallel lamellae with internal 
anionic surfaces and interlamellar cations for equilibrium 
and charge stabilization. Therefore, inclusion processes 
can occur with several different cations or small molecules, 
leading to substance encapsulation in the interlamellar space, 
increasing system tortuosity and water uptake.12 The use of 
MMTNa for acetate chlorhexidine inclusion has been previ-
ously reported,11 as has the use of βCD for CHX and NYS 
encapsulation.4,10 However, the use of water-soluble methyl-
β-cyclodextrin (MβCD) and hydroxypropyl-β-cyclodextrin 
(HPβCD) for CHX, and MMTNa for both drugs, are other 
possibilities to be studied in order to obtain stable formula-
tions with tolerable taste.13
Although there are several techniques to obtain CD 
complexes, such as co-precipitation, paste complexation, 
extrusion, spray drying, and kneading,6,13–15 considering 
these drugs, most of the authors show only the application 
of solution technique. Taking into account the industrial 
  applicability, it has become necessary to evaluate other 
options, as kneading, due the feasibility and low cost.
The aim of this study is the development of new nano-
structured drug-delivery systems with industrial applicability 
containing classical drugs for control of buccal pathologies, 
NYS and CHX, in order to increase the drug stability and 
improve the taste and antimicrobial action. Prepared and 
tested were inclusion complexes of NYS and CHX with 
MMTNa, and CHX with βCD and two derivatives, MβCD 
and HPβCD.
Materials and methods
Materials
Ethanol 95% (Merck, Darmstadt, Germany), MMTNa (Acros 
Chemical Co, Pittsburgh, PA), βCD, MβCD, and HPβCD 
(Wacker GmbH, Munich, Germany), NYS and chlorhexidine 
(Sigma, St Louis, MO) were pharmaceutical grade. Solutions 
were prepared with purified water obtained using a Milli-Q® 
system (Millipore, Bedford, MA).
Preparation of cD complexes
The inclusion complexes CHX:CD were prepared by 
solubilization-freeze-drying and kneading at molar ratios of 
1:1, 1:2, and 1:3, using βCD, MβCD, and HPβCD. Physical 
mixtures were prepared by mixing together CD and freeze-
dried CHX in a mortar at the same molar ratios. Using the 
kneading method, CD and CHX were mixed in a mortar 
for 5 minutes. An ethanol:water (70:30; v/v) solution was 
added, and the system mixed for 30 minutes to obtain a 
homogeneous paste. The paste was dried under reduced pres-
sure and the granulometry adjusted using a 40 mesh sieve. 
Using the solution method, the appropriate proportions of 
CHX and CD were mixed in 20 mL of distilled water using 
a magnetic stirrer for 72 hours. The samples were frozen in 
liquid nitrogen and lyophilized. The particle size was also 
calibrated with a 40 mesh sieve. The inclusion yield was 
calculated by ultraviolet (UV) spectroscopy.
Preparation of clay-based nanosystems
NYS and CHX:MMTNa nanosystems were prepared with 
the solution method using different cation exchange capacity 
(CEC) values: 100%, 80%, and 60% of the total MMTNa. 
The CEC value considered was 100 meqv of cation to 100 g 
of MMTNa.12 The inclusion reactions were performed in trip-
licate for different periods (1, 18, 24, and 48 hours), stirring 
at room temperature. The reaction mixtures were centrifuged 
at 4000 rpm for 40 minutes, and the precipitates dried in a International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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vacuum desiccator. The inclusion yield was calculated by 
UV spectroscopy.
characterization of nanosystems
These nanosystems were characterized by X-ray powder 
diffraction (XRPD), Fourier transform infrared spectros-
copy (FTIR), and differential scanning calorimetry (DSC). 
XRPD patterns of nanosystems, physical mixtures, and 
pure substances were recorded with a Rigaku Miniflex 
  diffractometer BD11197 (Rigaku, Tokyo, Japan) using CuKα 
radiation with a current of 30 mA, voltage of 40 kV , and a 
2θ angle between 2° and 20°. FTIR spectra were collected 
by an IR Prestige-21   Shimadzu A210045 (Shimadzu, Kyoto, 
Japan) spectrometer using 2% KBr pellets and wavenumber 
between 4000 and 400 cm−1. DSC analyses were carried out 
with DSC 882e Mettler-Toledo equipment (Mettler-Toledo, 
Greifensee, Switzerland) using hermetically sealed aluminum 
pans under a nitrogen flow of 28 mL⋅min−1 and heating rate 
of 10°C ⋅ min−1.
evaluation of nanosystem antimicrobial 
activity
The S. mutans (ATCC25175) and C. albicans (ATCC36901) 
strains were grown at 37°C for 24 hours in the presence of 
the two drugs being tested and the isolated carriers (CD and 
MMTNa), with simultaneous comparison with the CHX and 
MMTNa nanosystems and CHX 0.12% solution formula-
tions. The inoculum containing 106 cells/mL was uniformly 
seeded on plates containing solid brain heart infusion broth. 
After drying the surface, 10 µL of each sample was placed on 
the culture medium surface and incubated for 24 and 48 hours 
at 37°C. The plates containing S. mutans were maintained in 
anaerobiosis for the incubation time. The inhibition effect 
was verified by the presence of inhibition zones around the 
area on the plate where the solution was deposited and sized 
for analysis and comparison.
New chX nanosystem formulations  
and stability test analysis
Mouthwash formulations were developed with CHX 
(0.120% w/v) or with CD inclusion complexes. Water-
soluble mint essence (0.1% v/v), ethanol (0.050% v/v), 
polysorbate 20 (0.500% v/v), sorbitol (70% w/w aqueous 
solution, 15.0% v/v), menthol (0.010% w/v), and water 
(20%) were mixed until complete dissolution, and the vol-
ume was adjusted to 100% with water. The formulations 
were assayed by high efficiency liquid chromatography 
(HPLC) as described below. The HPLC system used was 
a LC-10 A/VP   Shimadzu (Shimadzu, Kyoto, Japan) with 
a chromatography C18 column (250 mm × 4.6 mm, 5 µm 
particle size), the mobile phase was methanol:water with 
triethylamine 0.4% (63:37; v/v) with a 0.8 mL ⋅ min−1 flow 
rate. The analysis was performed at room temperature, with 
a 20 µL injection volume and monitored at a wavelength of 
240 nm. The running time was established at 15 minutes.6,16 
The stability tests were performed based on International 
Conference on Harmonization guidelines17 with CHX 
alone and inclusion complex the CHX:βC, CHX:MβCD, 
and CHX:HPβCD. All the inclusion complexes were at a 
molar ratio of 1:1 and obtained by kneading. The formula-
tions were conditioned in a Nova Ética (São Paulo, Brazil) 
climatic chamber set to a relative humidity of 45°C ± 2°C 
and 75% ± 5%. The CHX:HPβCD inclusion complex 
preparation, formulation, and stability evaluation have not 
yet been described in the literature. The CHX assay was 
carried out according to the USP 34.6,16
statistical data analysis
One-way analysis of variance and Wilcoxon matched pairs 
tests were used to analyze all data obtained in this study 
using StatSoft® STATISTICA (StatSoft Inc, Tulsa, OK) 
software.
Results and discussion
Preparation and characterization  
of chX and cD inclusion complexes
XRPD patterns of lyophilized CHX, βCD, and CHX:βCD 
complex are presented in Figure 1. As expected, lyophilized 
CHX shows an amorphous pattern after water uptake, while 
βCD shows a highly crystalline pattern. The XRPD pat-
terns of the inclusion complexes show greater amorphous 
characteristics than pure βCD and physical mixtures. This 
is evidence of inclusion, as this disorder phenomenon has 
already been described by Cortés and colleagues.18 These 
amorphous patterns are characterized by the disappearance 
and decrease of peak intensity – a decrease of 70%–80% 
with the kneading method and 80%–90% with the solution 
method. These amorphous patterns were observed at molar 
ratios of 1:1, 1:2, and 1:3.
The FTIR spectra of the βCD inclusion complex (data 
not shown) showed the characteristic peaks of CHX at 
1700–1500 cm−1, corresponding to aromatic ring C = C 
stretching which is different from the βCD peaks. The spectra 
of both the physical mixture and the complex illustrated the 
typical peaks of each material of which the inclusion   complex 
is composed, with the presence of significant frequency International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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shifts. These results demonstrate the efficacy of the inclusion 
process with a CHX presence.18
As observed for βCD, MβCD presents a crystalline 
pattern (XRPD) and inclusion is evidenced by sample 
amorphization. The peak decrease was observed in samples 
prepared by both methods and at all molar ratios: 1:1, 1:2, 
and 1:3. In this case, it was not possible to differentiate 
between the two inclusion methods by XRPD. This lack 
of crystallinity indicates inclusion complex formation 
as shown by Figueiras and colleagues.19 The character-
istic peaks of both CHX and MβCD can be seen in the 
FTIR spectra of the inclusion complexes with significant 
shifts, confirming the presence of CHX in the inclusion 
processes.
The characteristic peaks of HPβCD are at 2θ angles of 
11.4° and 19.3°. A 60% peak reduction can be observed in 
the XRPD pattern of the complex produced by kneading at a 
1:1 molar ratio. The samples produced by the solution method 
did not show significant peak reduction, meaning that the 
method employed is determinative to this complex   formation. 
Wang and colleagues observed the same characteristics 
producing trans-ferulic acid complexes.20 The characteristic 
peaks of both CHX and HPβCD were demonstrated by the 
FTIR spectra of the inclusion complexes with significant 
shifts, confirming the effect of the presence of CHX in the 
production processes.
Thermal analysis, which is based on the comparison of 
the thermal behavior of single components, their physical 
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Figure 1 X-ray powder diffraction patterns of (A) chX and βcD, (B–D) physical mixture and inclusion complexes obtained by solubilization-freeze-drying and kneading 
at 1:1 (B), 1:2 (C), and 1:3 (D) molar ratios.
Abbreviations: βcD, β-cyclodextrin; chX, chlorhexidine; K, kneading; PM, physical mixture; s, solubilization-freeze-drying.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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mixture, and inclusion complexes, is the usual technique 
for qualitative investigation of CD inclusion complex for-
mation.21 DSC curves for the pure substances and inclusion 
compounds are shown in Figure 2. The DSC curve of CHX 
shows stability from 25°C to 174°C, after which, a sequence 
of thermal decomposition events were observed. DSC curves 
of inclusion compounds show that the CHX degradation peak 
temperature was higher for all inclusion complexes obtained 
with βCD and its synthetic derivatives (MβCD and HPβCD). 
This evidences a new supramolecular compound formation 
characteristic of inclusion complexes with improved stabil-
ity. The disappearance or flattening of the drug melting 
point peak are considered conclusive evidence of inclusion 
compound formation.21 Yallapu and colleagues have observed 
these same patterns for curcumin complexation, where the 
melting endothermic peak of the drug completely disappeared 
in the DSC curves.22
In all CD derivatives studied, the kneading method was 
chosen to prepare inclusion complexes of CHX, βCD, MβCD, 
and HPβCD at a 1:1 molar ratio, due its low cost and indus-
trial applicability.
Preparation and characterization  
of clay-based nanosystems
MMTNa was used as a nanocarrier due to its sustained 
release properties and synergistic antimicrobial activity. 
The nanosystems produced were characterized by XRPD, 
DSC, and FTIR. A decrease in the 2θ value observed in 
the XRPD analysis is an indicative factor of the inclusion 
process since a reduction in this angle is associated with an 
increase in basal spacing, which is related to drug inclusion.23 
The chlorhexidine nanosystem obtained showed a 2θ value 
decrease, described in Table 1, when compared with pure 
MMTNa, indicating the success of the inclusion process. 
However, there is no significant difference between all the 
proposed conditions presented in Table 1 (P . 0.05). CHX 
molecule rearrangement should also be considered since, 
like an alkyl ammonium chain, CHX may have a particular 
conformation that expands basal spacing in low concentration 
between lamellae. Absorption of CHX can occur when a high 
concentration is used for inclusion. In order to avoid this, a 
60% CEC was used (24 hours). Under these conditions, the 
inclusion complex presented an average lamellar spacing 
of 16.8 ± 1.3 Å and an inclusion yield of 70.0% ± 0.02%. 
These results corroborate those observed by Meng and 
colleagues11 and Yang and colleagues,24 who reported an 
interlamellar space increase from 15.1 to 19.4 Å and 14.5 to 
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Figure 2 Differential scanning calorimetry curves of chX, βcD, MβcD, hPβcD, 
and inclusion complexes obtained by kneading at a 1:1 molar ratio.
Abbreviations: βcD, β-cyclodextrin; chX, chlorhexidine; hPβcD, hydroxypropyl-
β-cyclodextrin; K, kneading; MβcD, methyl-β-cyclodextrin; Temp, temperature.
Table  1  Inclusion  process  results  obtained  with  MMTNa 
and chX
Intercalation 
conditions
2θ (°) Basal  
spacing (Å)
Indirect 
yield (%)
MMTNa
MMTNa 6.55 13.81   –
CHX:MMTNa
chX:MMTNa 60% 1 h c1 5.25 16.83 71
18 h c2 5.40 16.37 71
24 h c3 5.05 17.50 70
48 h c4 5.20 16.99 79
chX:MMTNa 80% 1 h c5 5.00 17.67 50
18 h c6 5.05 17.50 58
24 h c7 5.10 17.33 61
48 h c8 5.20 16.99 76
chX:MMTNa 100% 1 h c9 5.00 17.67 36
18 h c10 5.00 17.67 45
24 h c11 5.10 17.33 46
48 h c12 4.95 17.85 50
Abbreviations: chX, chlorhexidine; h, hour; MMTNa, sodium montmorillonite.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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16.6 Å, respectively, for CHX acetate. These authors have 
observed that the CHX molecular volume is around 0.5 nm, 
slightly less than the 0.69 nm calculated by subtracting the 
MMTNa monolayer size (0.96 nm) from the basal spacing 
measurement (1.65 nm). This larger molecular volume may 
be due to a different conformation assumed by CHX in 
MMTNa lamellae.11
DSC curves for the pure substances and nanosystems are 
shown in Figure 3. Nanosystem C3 shows an endothermic 
peak between 200°C and 220°C, which may indicate the 
release of CHX from lamellar spacing. This result may be 
evidence that substances intercalated between clay lamellae 
can be observed through the calorimetric patterns of nano-
systems at different temperatures.24
FTIR spectra of pure CHX, MMTNa, physical mixtures, 
and nanosystems present characteristic stretching bands due 
to water absorption at 3462 cm−1, 3400 cm−1, and 3420 cm−1. 
The hydroxyl group from the Al-OH bond presents a stretch-
ing band at around 3620 cm−1. Vibration bands of silicate 
between montmorillonite lamellae are shown at 1114 cm−1 
and 1047 cm−1 for the Si-OH bond.11,25 Regarding the spectra 
of CHX, this shows a shift of the stretching bands for the 
aromatic N-H and C-H bonds at 3396 cm−1 and 3226 cm−1 
respectively. It is important to note that the spectra of the 
physical mixture, which simulates C3, showed differences 
when compared with the spectra of the inclusion process, 
indicating their contrasting profiles and confirming the inclu-
sion process.
The NYS:MMTNa inclusion studies showed a 2θ value 
decrease in relation to pure MMTNa, which is evidence of 
nanosystem formation under all tested conditions (Table 2). 
However, the 24-hour inclusion period produced a larger 
basal spacing with all tested CEC. The nanosystem N3 (60% 
CEC) was chosen for characterization due to the higher basal 
spacing compared with 100% CEC and the economic aspect. 
This nanosystem presented an average lamellae spacing of 
16.63 ± 0.33 Å (Figure 4) and an indirect inclusion yield of 
54% ± 0.01%.
XRPD profiles for the pure substances and nanosystem 
N3 at different CEC values are shown in Figure 4. Nano-
system N3 shows a higher 2θ value when compared with 
MMTNa. This result is evidence of inclusion complex for-
mation in the clay lamellae.
The calorimetric pattern of NYS derivatives are shown in 
Figure 5. The characteristic thermal event related to NYS, its 
melting point, occurs between 160°C and 180°C, but this is 
not registered on the DSC curve of the NYS:MMTNa 60% 
CEC – 24-hour nanosystem. This pattern is similar to the 
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Figure 3 Dsc curves of MMTNa, chX, and nanosystems with 60% cec – 24 hours (c3).
Abbreviations: cec, cation exchange capacity; chX, chlorhexidine; Dsc, differential scanning calorimetry; MMTNa, sodium montmorillonite.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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pure MMTNa with an endothermic peak at 100°C due to 
water loss. The absence of NYS endothermic melting point 
is evidence of inclusion, since the presence of the drug in 
the nanosystem was confirmed by FTIR analysis (data not 
shown).
evaluation of antimicrobial activity
The inhibition halo technique has the greatest applicability 
in the evaluation of antimicrobial activity of biologically 
active montmorillonite–chlorhexidine nanocomposite.24,26 
Therefore, the inhibition halo technique was used to 
evaluate and compare the activity of the nanosystems 
and pure drugs and the possible synergy of the drugs 
with clays and CD. The samples tested were CHX:βCD, 
CHX:MβCD, and CHX:HPβCD. These nanosystems 
were prepared by kneading, using CHX and CDs at a 
1:1 molar ratio. The control solution was 0.12% CHX 
aqueous solution (w/v). The inhibition halo diameters 
observed for C. albicans and S. mutans are shown in 
Table 3. All samples showed very similar activity and 
were quite similar to the CHX aqueous solution against 
Gram-positive bacteria and fungi. However, Cortés and 
colleagues18 have shown that a CHX:βCD inclusion com-
plex demonstrated modified antimicrobial activity when 
its minimum inhibitory concentration was measured, 
increasing its efficacy against pathogenic bacteria. These 
results were not observed in this work. Herein, contrary 
results were obtained with no statistical difference in the 
samples tested (P = 0.07653).
The halo diameters of the MMTNa nanosystems are 
represented in Table 4 and Figure 6. The MMTNa suspen-
sion did show any inhibition activity, which corroborates 
results shown by other authors.11,24,26,27 These authors not 
only tested sodium but also calcium montmorillonite. Thus, 
any synergic effect can be attributed to the absorptive prop-
erties of clay.
CHX aqueous solution 0.12% and the C3 derivative 
showed a large growth inhibition zone for both microor-
ganisms. Halos for the CHX solution against S. mutans 
were between 26 and 27 mm, while the C3 derivative 
presented halos of around 21–22 mm. Furthermore, halos 
against C. albicans of 18, 19, and 26 mm were observed 
using the CHX solution, and 11, 12, and 20 mm with the 
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Figure 4 X-ray powder diffraction patterns of MMTNa and NYs-and-MMTNa nanosystems (NYs:MMTNa) with 60% cec – 24 hours (N3).
Abbreviations: cec, cation exchange capacity; MMTNa, sodium montmorillonite; NYs, nystatin.
Table 2 Inclusion process results obtained with MMTNa and NYs
Intercalation  
conditions
2θ (°) Basal  
spacing (Å)
Indirect  
yield (%)
NYs:MMTNa 60% 1 h N1 5.90 14.98 51
18 h N2 5.65 15.64 52
24 h N3 5.20 16.99 54
48 h N4 5.95 14.85 46
NYs:MMTNa 80% 1 h N5 5.45 16.22 53
18 h N6 5.60 15.78 49
24 h N7 5.20 16.99 55
48 h N8 5.75 15.37 43
NYs:MMTNa 100% 1 h N9 5.40 16.37 47
18 h N10 5.60 15.78 46
24 h N11 5.55 15.92 51
48 h N12 6.00 14.73 44
Abbreviations: h, hour; MMTNa, sodium montmorillonite; NYs, nystatin.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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indicating that the release is possibly slower than chlor-
hexidine due to lower NYS solubility in water and saliva. 
However, the large fluid volume in vivo could lead to a 
more effective release, justifying the use of this nanosystem 
in prolonged release tablets, which could be a therapeutic 
alternative to more complex pharmaceutical forms.
Development of inclusion complexes  
in oral solutions and stability test
Initially, the CHX stability in a mouthwash formulation 
was investigated because CHX has several incompatibilities 
with common excipients, such as some ions and organic 
compounds. These incompatibility reactions lead to the 
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Figure 5 Dsc curves of MMTNa, NYs, physical mixture of 60% cec (NYs:MMTNa PM), and NYs:MMTNa 60% cec – 24-hour nanosystem (N3).
Abbreviations:  cec,  cation  exchange  capacity;  Dsc,  differential  scanning  calorimetry;  MMTNa,  sodium  montmorillonite;  NYs,  nystatin;  PM,  physical  mixture; 
Temp, temperature.
Table 3 Inhibition halo diameters of chX (control) and inclusion 
complexes against Streptococcus mutans and Candida albicans
S. mutans  C. albicans
Inhibition halo diameters (mm)
chX:βcD 17 17 17 15 15 15
chX:MβcD 18 18 18 16 16 16
chX:hPβcD 17 17 17 16 15 15
chX 17 17 17 16 16 15
Abbreviations: βcD, β-cyclodextrin; chX, chlorhexidine; hPβcD, hydroxypropyl-
β-cyclodextrin; MβcD, methyl-β-cyclodextrin.
Table  4  Inhibition  halo  diameters  of  pure  substances  and 
developed derivatives against Streptococcus mutans and Candida 
albicans strains using three different plating techniques
S. mutans C. albicans
Plate 1 Swab 1a Swab 2b Plate 1 Swab 1a Swab 2b
Inhibition halo diameters (mm)
MMT 0 0 0 0 0 0
chX 27 26 27 18 19 26
c3c 22 21 21 11 12 20
NYs 0 0 0 16 19 27
N3d 0 0 0 0 0 0
Notes:  aswab  1  samples  applied  in  drops;  bswab  2  samples  applied  to  wells; 
cc3  =  chX:MMTNa  60%  cec  –  24  hours;  dN3  =  NYs:MMTNa  60%  cec  – 
24 hours.
Abbreviations:  cec,  cation  exchange  capacity;  chX,  chlorhexidine;  MMT, 
montmorillonite; MMTNa, sodium montmorillonite; NYs, nystatin.
C3 derivative. The smaller halo diameters presented by the 
C3 derivative were expected since it is an inclusion product 
with known prolonged release characteristics.24,27 Yang and 
colleagues24 studied the antimicrobial activity of chlorhexi-
dine acetate:MMTNa nanosystems and found that CHX was 
released slowly and the inhibition halo could be seen after 
1 year. However, the results of this present study show that 
the CHX C3 derivative presented acceptable immediate 
release properties without total drug release, which is ideal 
for the treatment of oral diseases.
Pure NYS, an antifungal agent, did not show any inhibi-
tion activity against S. mutans, as expected, but presented 
halos ranging from 16, 19, and 27 mm against C. albicans 
strains (Table 4, Figure 6). These results are similar to those 
found by Carrillo-Muñoz and colleagues of 20 mm.28 The 
NYS nanosystem was expected to show the same prolonged 
release profile as C3, but did not present any initial   inhibition, International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Dovepress
2589
Nanosystems for the control of oral pathogens
formation of the degradation product p-chloroaniline and 
its subsequent precipitation.29,30 No precipitation or incom-
patibility was observed between CHX and formulation 
excipients 48 hours after formulation preparation with pure 
CHX. Mouthwash formulations were produced with pure 
CHX and the inclusion complexes using 0.12% w/v CHX 
content. These samples were stored in a climatic chamber at 
45°C ± 2°C and 75% ± 5% relative humidity (RH) in order 
to evaluate the thermal stability. The results of the stability 
study are presented in Figure 7, and a great increase in the 
stability of all nanosystems studied can be seen, indicating 
the potential for the commercial application of these new 
CD derivatives.
Conclusion
XRPD, FTIR, and DSC analysis were used to confirm the 
  proposed nanosystems formation and the suitability of the pro-
duction methods. However, the nanosystems that showed best 
antimicrobial effect were CHX and CD inclusion   complexes 
and CHX:MMTNa 60% CEC – 24 hours. Although NYS 
nanosystems presented no antimicrobial activity with the 
technique applied here, this does not   preclude their use since 
this method does not represent   in-vivo conditions.   Moreover, 
these nanosystem formulations present the following 
improvements: higher stability for all chlorhexidine inclu-
sion complexes compared with pure chlorhexidine under 
40°C ± 2°C and 75% ± 5% RH and being a sustained release 
system, the potential for NYS nanosystems to mask the bitter 
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Figure 6 Inhibition halo analysis using (A) Streptococcus mutans (n = 3) and (B) Candida albicans strains (n = 3) of chX aqueous solution 0.12%, chX derivative 60% cec – 
24 hours (c3), NYs, NYs derivative 60% cec – 24 hours (N3), and MMTNa.
Note: The inoculum in all Petri dishes followed the order displayed on the first dish.
Abbreviations: chX, chlorhexidine; MMTNa, sodium montmorillonite; NYs, nystatin.
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Figure 7 Stability profile of mouth wash formulation containing CHX not included, 
and inclusion complexes of βcD, MβcD, and hPβcD stored at 40°c ± 2°c and 
75% ± 5% relative humidity for 6 months.
Abbreviations: βcD, β-cyclodextrin; chX, chlorhexidine; hPβcD, hydroxypropyl-
β-cyclodextrin; MβcD, methyl-β-cyclodextrin.International Journal of Nanomedicine
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taste, justifying subsequent in-vivo studies. For these reasons, 
further studies are being carried out to evaluate their applica-
tion in professional formulations.
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